Abstract
Background
Emphasis is often placed on the good recovery of vision following optic neuritis (ON). However, patients continue to perceive difficulties in performing everyday visual tasks and have reduced visual quality of life. This is in addition to documented permanent loss of retinal volume.
Methods
Seventy-five subjects following monocular ON (> 3 months prior to assessment), were evaluated by the Rabin cone contrast test (CCT). Red, green and blue cone contrast scores were extracted for the affected and fellow eyes. Retinal nerve fiber layer (RNFL) and macular volume (MV) were assessed using optical coherence tomography.
Results
Fifty-seven patients had multiple sclerosis and 17 had clinically isolated syndrome. Median time from ON to evaluation was 47 months. Expanded Disability Status Scale (EDSS) ranged between 0 and 6.5 with average of 2 ± 1.3. Cone contrast scores for red, green and blue in the affected eyes were significantly lower than in the fellow eyes. RNFL thickness and MV were reduced in the affected compared to the fellow eyes. Positive correlations between CCT and RNFL were found in both eyes, but much stronger in the affected eyes (r = 0.72, 0.74, 0.5 and 0.53, 0.58, 0.46 for red green and blue in each eye, respectively). Positive correlations between CCT and MV were found in both eyes, but only modestly stronger in the affected eyes.
Conclusions
Impaired chromatic discrimination thresholds quantitatively document persistent functional complaints after ON. There is evidence of dysfunction in both the affected eye and the fellow eye.
Similar content being viewed by others
References
Galetta SL et al (2015) Acute optic neuritis: unmet clinical needs and model for new therapies. Neurol Neuroimmunol Neuroinflamm 2(4):e135
Hanson JV et al (2016) Optical coherence tomography in multiple sclerosis. Semin Neurol 36(2):177–184
Beck RW et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581–588
No authors listed (1997) Visual function 5 years after optic neuritis: experience of the optic neuritis treatment trial. The Optic Neuritis Study Group. Arch Ophthalmol 115(12):1545–1552. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/642401
Katz B (1995) The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial. Trans Am Ophthalmol Soc 93:685–708
Schneck ME, Haegerstrom-Portnoy G (1997) Color vision defect type and spatial vision in the optic neuritis treatment trial. Invest Ophthalmol Vis Sci 38(11):2278–2289
Cranwell MB et al (2015) Performance on the Farnsworth-Munsell 100-Hue test is significantly related to nonverbal IQ. Invest Ophthalmol Vis Sci 56(5):3171–3178
Lampert EJ et al (2015) Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. J Neurol 262(11):2491–2497
Martinez-Lapiscina EH et al (2014) Colour vision impairment is associated with disease severity in multiple sclerosis. Mult Scler 20(9):1207–1216
Villoslada P et al (2012) Color vision is strongly associated with retinal thinning in multiple sclerosis. Mult Scler 18(7):991–999
Rabin J, Gooch J, Ivan D (2011) Rapid quantification of color vision: the cone contrast test. Invest Ophthalmol Vis Sci 52(2):816–820
Fujikawa M et al (2018) Evaluation of clinical validity of the Rabin cone contrast test in normal phakic or pseudophakic eyes and severely dichromatic eyes. Acta Ophthalmol 96(2):e164–e167
Balcer LJ et al (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68(16):1299–1304
Raftopoulos R et al (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15(3):259–269
Green AJ et al (2017) Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet 390(10111):2481–2489
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical trials of new agents in multiple sclerosis. Neurology 46(4):907–911
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452
Schippling S et al (2015) Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler 21(2):163–170
Cruz-Herranz A et al (2016) The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology 86(24):2303–2309
Mowry EM et al (2009) Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry 80(7):767–772
Raz N et al (2011) Sustained motion perception deficit following optic neuritis: behavioral and cortical evidence. Neurology 76(24):2103–2111
Almog Y, Nemet A (2010) The correlation between visual acuity and color vision as an indicator of the cause of visual loss. Am J Ophthalmol 149(6):1000–1004
Porciatti V, Sartucci F (1996) Retinal and cortical evoked responses to chromatic contrast stimuli. Specific losses in both eyes of patients with multiple sclerosis and unilateral optic neuritis. Brain 119(Pt 3):723–740
Evangelou N et al (2001) Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 124(Pt 9):1813–1820
Toussaint D et al (1983) Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis. J Clin Neuroophthalmol 3(3):211–220
Green AJ et al (2010) Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain 133(Pt 6):1591–1601
Oberwahrenbrock T et al (2013) Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler 19(14):1887–1895
Brandt AU et al (2011) Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 134(Pt 11):e193 (author reply e194)
Balcer LJ et al (2015) Vision and vision-related outcome measures in multiple sclerosis. Brain 138(Pt 1):11–27
Acknowledgements
Netta Levin and Ari Green thank the Feldman foundation for their support for Professor Levin’s sabbatical at UCSF.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Levin, N., Devereux, M., Bick, A. et al. Color perception impairment following optic neuritis and its association with retinal atrophy. J Neurol 266, 1160–1166 (2019). https://doi.org/10.1007/s00415-019-09246-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-019-09246-8